Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Schrödinger auf Morgan Stanley Healthcare-Konferenz: Cloud-Umstellung gewinnt an Fahrt (Investing.com DE) +++ SCHROEDINGER Aktie +5,40%

SCHROEDINGER Aktie

 >SCHROEDINGER Aktienkurs 
17.725 EUR    +8.1%    (TradegateBSX)
Ask: 17.885 EUR / 900 Stück
Bid: 17.8 EUR / 900 Stück
Tagesumsatz: 1180 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
SCHROEDINGER Aktie über LYNX handeln
>SCHROEDINGER Performance
1 Woche: -4,8%
1 Monat: +0,6%
3 Monate: +33,9%
6 Monate: +49,3%
1 Jahr: +2,3%
laufendes Jahr: +8,4%
>SCHROEDINGER Aktie
Name:  SCHRÖDINGER INC.
Land:  USA
ISIN/ Wkn:  US80810D1037 / A2PY7M
Symbol/ Ticker:  43Z (Frankfurt) / SDGR (NASDAQ)
Kürzel:  FRA:43Z, ETR:43Z, 43Z:GR, NASDAQ:SDGR
Index:  -
Profil:  Schrödinger, Inc. is a life sciences software and biotechnology company that develops a physics-based computational platform for molecular discovery. The company provides software tools used to model and simulate chemical and biological systems, hel..
>Volltext..
Marktkapitalisierung:  1226.7 Mio. EUR
Unternehmenswert:  954.31 Mio. EUR
Umsatz:  223.33 Mio. EUR
EBITDA:  -127.24 Mio. EUR
Nettogewinn:  -46.85 Mio. EUR
Gewinn je Aktie:  -0.63 EUR
Schulden:  93.1 Mio. EUR
Liquide Mittel:  252.54 Mio. EUR
Operativer Cashflow:  -109.38 Mio. EUR
Bargeldquote:  2.41
Umsatzwachstum:  12.3%
Gewinnwachstum:  69.09%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel -
Suchwörter:  SCHROEDINGER, SCHRÖDINGER, SCHRODINGER
Letzte Datenerhebung:  14.09.26
>SCHROEDINGER Kennzahlen
Aktien/ Unternehmen:
Aktien: 65.64 Mio. St.
Frei handelbar: 96.42%
Rückkaufquote: -0.13%
Mitarbeiter: 850
Umsatz/Mitarb.: 0.26 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 13.38%
Bewertung:
KGV: -
KGV lG: -
KUV: 5.73
KBV: 4.26
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 56.87%
Gewinnmarge: -20.98%
Operative Marge: -59.24%
Managementeffizenz:
Gesamtkaprendite: -8.18%
Eigenkaprendite: -16.18%
>SCHROEDINGER Peer Group
Elektronik / Software
 
14.09.26 - 20:54
Schrödinger auf Morgan Stanley Healthcare-Konferenz: Cloud-Umstellung gewinnt an Fahrt (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
09.09.26 - 13:06
Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs (Business Wire)
 
Tectora secures $55 million Series A investment from NEA and RA Capital ManagementNEW YORK--(BUSINESS WIRE)--$SDGR #AI--Schrödinger, Inc. (Nasdaq: SDGR) today announced the formation of Tectora, a new biotechnology company it co-founded with New Enterprise Associates (NEA) and RA Capital Management, focused on developing innovative therapies for immunology and inflammation. Tectora concurrently closed a $55 million Series A investment from NEA and RA Capital. In connection with the transaction, Schrödinger contributed two early-stage small molecule programs (SDGR-4594 and SDGR-8139) and, in exchange, received an equity stake in Tectora and is also eligible to receive future milestones and royalties. Tectora will partner with Schrödinger's drug discovery experts and leverage Schrödinger's computational platform at scale to further advance these programs to clinical candidates. “Schrödinger has a track record of creating and enabling programs for licensing to pharma companies or joining forces with...
18.08.26 - 11:30
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci (Zacks)
 
AI is reshaping drug discovery, with Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci advancing computational platforms and pipelines....
14.08.26 - 14:33
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
 
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 12, 2026, the company granted restricted stock units (RSUs) with respect to 3,315 shares of the company's common stock to two newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The RSUs vest over four years, with 25 percent of such RSUs vesting when such employee completes 12 months of continuous service measured from the vesting commencement date, and the balance of the RSUs vesting in a series of successive equal yearly installments of 1/4 of the original number of RSUs upon each such employee's completion of each additi...
13.08.26 - 01:12
Schrödinger (SDGR) Q2 2026 Earnings Call Transcript (Fool)
 
AI co-scientist Bunsen drives productivity gains amid software model shift....
06.08.26 - 11:48
Schrödinger and BMS expand partnership to deploy AI for drug discovery (PBR)
 
This initiative builds on an established partnership between the two companies, under which BMS already utilises Schrödinger's computational platform for drug discovery projects. The new arrangement will extend The post Schrödinger and BMS expand partnership to deploy AI for drug discovery appeared first on Pharmaceutical Business review....
05.08.26 - 23:24
Earnings Call: Schrödinger übertrifft Prognosen für Q2 2026 – Aktie legt zu (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
22.07.26 - 14:36
Schrödinger to Announce Second Quarter 2026 Financial Results on August 5 (Business Wire)
 
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs. To learn more, visit www.schrodinger.com, follow us on LinkedIn, or visit our blog, Extrapolat...
20.07.26 - 14:33
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
 
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on July 16, 2026, the company granted restricted stock units (RSUs) with respect to 3,691 shares of the company's common stock to four newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.The RSUs vest over four years, with 25 percent of such RSUs vesting when such employee completes 12 months of continuous service measured from the vesting commencement date, and the balance of the RSUs vesting in a series of successive equal yearly installments of 1/4 of the original number of RSUs upon each such employee's completion of each addition...
18.07.26 - 03:01
Insiderhandel: EVP & CFO verkauft Aktien von Schrodinger im Wert von 13647 USD (Insiderkauf)
 
Jain, Rachit - Vorstand - Tag der Transaktion: 2026-07-16...
13.07.26 - 12:48
Media Deals: Great for Bankers, Usually Not for You (WSJ EN)
 
Plus, let's just call it Schrödinger's Strait....
27.06.26 - 15:01
Schrödinger′s Strait of Hormuz: Open or Closed? (Bloomberg)
 
Despite a ship being struck in the Strait of Hormuz on Thursday and another incident over the weekend, some vessels continue to travel the strait on both the Iranian and Omani sides. However, overall traffic remains significantly reduced compared to pre-conflict levels, with daily ship movements down from over 140 in February to approximately 30-40 currently. Bloomberg News Energy & Commodities Reporter Stephen Stapczynski joins Bloomberg This Weekend to explain to hosts David Gura and Christina Ruffini that safety concerns persist, causing ship owners, captains, and energy exporters to reassess the risks of passage through this critical waterway. (Source: Bloomberg)...
18.06.26 - 14:33
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
 
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on June 12, 2026, the company granted restricted stock units (RSUs) with respect to 10,771 shares of the company's common stock to seven newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The RSUs vest over four years, with 25 percent of such RSUs vesting when such employee completes 12 months of continuous service measured from the vesting commencement date, and the balance of the RSUs vesting in a series of successive equal yearly installments of 1/4 of the original number of RSUs upon each such employee's completion of each addit...
02.06.26 - 23:48
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? (Fool)
 
Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation....
22.05.26 - 14:33
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
 
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on May 18, 2026, the company granted (i) a non-statutory stock option to purchase 1,875 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 18,766 shares of the company's common stock to seven newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The stock option has an exercise price of $12.05 per share, equal to the closing price of the company's common stock on May 18, 2026. The stock option has a ten-year term and vests over four years, with 25 percent of the shar...
06.05.26 - 01:46
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
 
Schrodinger (SDGR) delivered earnings and revenue surprises of -44.64% and -2.17%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?...
06.05.26 - 00:24
Schrödinger (SDGR) Q1 2026 Earnings Transcript (Fool)
 
Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...
05.05.26 - 22:06
Schrödinger Reports First Quarter 2026 Financial Results (Business Wire)
 
First Quarter ACV of $28 Million, Representing 12% Growth Continued Momentum in Transition to Hosted Software Licensing Schrödinger to Launch Bunsen, an Agentic AI Co-Scientist, This Summer Lilly's Announced $2.3 Billion Acquisition of Ajax Validates Schrödinger's Track Record of High-Value CollaborationsNEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the quarter ended March 31, 2026. “Our first quarter results show strong growth in both ACV and drug discovery revenue. ACV growth of 12 percent was driven by usage scale-ups and new deployments; we are also pleased with our progress transitioning customers to hosted licensing. The biopharmaceutical funding environment is improving, and the depth of customer engagement reflects the critical importance of our computational platform that integrates ground truth simulation with leading edge AI. We have a strong commitment to technology leadership and are excited about the release this summer of Bunsen, an...
21.04.26 - 14:36
Schrödinger to Announce First Quarter 2026 Financial Results on May 5 (Business Wire)
 
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) will report its first quarter 2026 financial results on Tuesday, May 5, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs. To learn more, visit www.schrodinger.com, follow us on LinkedIn, or visit our blog, Extrapolations.c...
20.04.26 - 22:06
Hormuz Traffic At Standstill After US Ship Seizure (ZeroHedge)
 
Hormuz Traffic At Standstill After US Ship Seizure Confirming the Schrodinger nature of the notorious waterway, the Strait of Hormuz is now just closed even more than before Iran and the US said the vital oil channel had been reopened. Traffic through the strait on Sunday and Monday was reduced to a trickle following a Saturday surge, after Tehran rejected a continuing US naval blockade and moved to seal the waterway again. The reduced movement underscores just how quickly hopes unraveled that cargoes could once again resume. On Friday, Iran's Foreign Minister Abbas Araghchi said the strait was “completely open” for commercial shipping, while US President Donald Trump said Iran was removing sea mines from the waterway. That prompted oil prices to plunge and dozens of tankers to race toward the strait at the mouth of the Persian Gulf. But Iran quickly declared that the passage was closed again as it emerged that the US operation in place since April 13 would not be lifted. And rejected: t...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Ein Hafen ist ein reizvoller Aufenthalt für eine im Lebenskampf erschöpfte Seele. - Charles Baudelaire
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!